Bank Of New York Mellon Corp Terns Pharmaceuticals, Inc. Transaction History

Bank Of New York Mellon Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.5 - $3.0 $57,088 - $114,177	-38,059 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$2.83 - $6.7 $6,675 - $15,805	2,359 Added 6.61%	38,059 $112,000
Q4 2021 Feb 11, 2022	BUY	$5.65 - $10.73 $46,256 - $87,846	8,187 Added 29.76%	35,700 $253,000
Q3 2021 Nov 12, 2021	BUY	$7.22 - $13.46 $30,518 - $56,895	4,227 Added 18.15%	27,513 $287,000
Q2 2021 Aug 11, 2021	BUY	$12.26 - $22.0 $49,125 - $88,154	4,007 Added 20.78%	23,286 $285,000
Q1 2021 May 13, 2021	BUY	$17.13 - $27.25 $330,249 - $525,352	19,279 New	19,279 $424,000

167

78.3M

580K

454K

Ticker TERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,613,800
Market Cap $220M
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.